Thomson Reuters

Newport Horizon Premium™ is the most advanced product targeting, global business development and API sourcing system from Thomson Reuters, the industry authority on the global generics market.

Created specifically for demanding professionals in generic pharmaceutical companies, OTC and API manufacturers, it can help you to identify and evaluate new product development and licensing opportunities ahead of the competition.

Newport Horizon Premium includes the same data and features as the industry-standard Newport Horizon Global™ system, with the addition of current- and previous-year kilogram and International Units API consumption data by region by dose form, and routes of synthesis data for more than 2,500 APIs.

Powerful integrated API intelligence with unique analysis.

With Newport Horizon Premium, you can:

• Recognize critical patent, exclusivity and regulatory issues with candidate products.
• Discover early, exclusive sources of API supply.
• Profile competitors, business partners, and candidate products for acquisition, alliances, licensing, or supply and manufacturing.
• Track and monitor the launch, API development and patenting activities of competitors worldwide, including India and China.
• Evaluate candidate products against the earliest competitive intelligence.
• Evaluate new product development opportunities in 68 markets worldwide including India and China.
• Identify niche opportunities that match your strategic needs and unique research, sales or marketing strengths.
• Adjust your research timing, priorities and resources based on active competitive intelligence monitoring.
• Evaluate the best strategy based on kilogram API consumption data and trends and available routes of synthesis.
• Analyze and compare API consumption data and trends by region, and by dose form for the current and previous year.
• Analyze routes of synthesis together with required intermediates and reagents, in addition to the referenced patents and scientific literature.
  

Why choose Newport Horizon Premium?

• Unique strategic intelligence. Newport Horizon Premium incorporates the unique strategic intelligence and powerful competitive analysis that is only available from Thomson Reuters. It integrates intelligence on more than 40,000 launched products containing over 10,000 different active ingredients and over 20,000 corporate groups.
• Sophisticated targeting capabilities. Newport Horizon Premium can help you to profile promising new partner companies and secure early, exclusive sources of API supply. API consumption data and trends can be included in product-targeting searches, enabling you to find the most appropriate business opportunities quickly and accurately.
• Test and explore new business strategies. Newport Horizon Premium can help you to recognize potential barriers to market entry, and plan your development pipeline effectively. With the industry’s most sophisticated product targeting capabilities, it can significantly enhance your competitive edge.
  
  

• Sales, launch, approval and regulatory data for more than 40,000 launched products containing over 10,000 different active ingredients.
• Profiles of more than 20,000 companies and corporate groups, including subsidiary, launch, approvals, regulatory filings and APIs manufactured.
• Detailed manufacturing capabilities for approximately 500 sites.
• Alerting on key changes in products and companies, including new regulatory filings and approvals.
• Unique, early API manufacturing intelligence.
• Worldwide patent families and individual patents for more than 90 countries.
• Comprehensive Supplementary Protection Certificate (SPC) data for Europe.
• Projected loss of exclusivity dates for US, European and Japanese markets.
• Sales figures by molecule and by dosage form for major world market regions, including two-year sales history.
• Current retail and hospital dose pack pricing for each dose form and strength of all products in more than 68 countries.
• Paragraph IV patent challenges commentaries, including company identities, FTF and status of litigation for more than 200 products.
• Product launch and first market authorization data, country-by-country.
• Orange Book approved dose forms, US Drug Master Files, EU Certificates of Suitability, FDA warning letters and issues, and Japanese DMFs and DEA registrations.
• Labeling and prescribing data for more than 1,800 unique products.
• Routes of synthesis, including intermediates and reagents with patent and literature references for thousands of products.
• Chemical structure diagram and details of alternative structures for thousands of products.
• Powerful indexing and searching of products according to FDA approved indication and technology class.
• US market share breakdown by dose form and strength.
• Reports on key conferences affecting the generics industry.
• Ability to target products utilizing over 40 different search criteria.
• Kilogram and International Units API consumption data by region, by dose form for the current and previous year.